Skip to main content
Advertisement
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
ADVERTISEMENT
Guan Xing
Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia: Phase 1b Results
Introduction:
Paresh Vyas ;
Joshua F. Zeidner ;
Suman N. Kambhampati ;
David A. Sallman ;
Monzr M. Al Malki ;
Richard Larson ;
Adam Asch ;
Gabriel Mannis ;
Wanxing Chai-Ho ;
Tiffany N. Tanaka ;
Terrence J. Bradley ;
Deepa Jeyakumar ;
Eunice S. Wang ;
Guan Xing ;
Mark P. Chao ;
Giri Ramsingh ;
Camille Renard ;
Naval G. Daver ;
Indu Lal ;
11/04/2022
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
Introduction:
Naval G. Daver ;
Paresh Vyas ;
Guan Xing ;
Mark P. Chao ;
Giri Ramsingh ;
Camille Renard ;
David A. Sallman ;
Andrew H. Wei ;
11/04/2022
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Advertisement
Advertisement
Advertisement
Advertisement
Upcoming Events
November 23 – November 24
December 4 – December 5
December 6 – December 7
December 9 – December 11
December 9 – December 11
December 12 – December 13
December 14 – December 15
February 2 – February 5
February 27 – March 1
March 17 – March 19
See Full Calendar
Advertisement
Advertisement
Advertisement